Aeglea Biotherapeutics

OverviewSuggest Edit

Aeglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes which have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing of tumor cells. Aeglea’s first two programs utilize enzymes that degrade either the amino acid L-methionine (Met) or L-arginine (Arg) for use as therapy in oncology. The Company's therapeutic strategy takes advantage of decades of clinical validation to leverage the genetic and epigenetic basis of tumor AA auxotrophy to identify patients likely to benefit from these molecules.
TypePublic
Founded2013
HQAustin, US
Websiteaegleabio.com

Latest Updates

Employees (est.) (Dec 2019)76(+2%)
Revenue (FY, 2019)$0(-100%)
Share Price (Nov 2020)$8.6 (-4%)
Cybersecurity ratingAMore

Key People/Management at Aeglea Biotherapeutics

Ravi M. Rao

Ravi M. Rao

Chief Medical Officer
Charles N. York

Charles N. York

Chief Financial Officer
Michael C. Hanley

Michael C. Hanley

Chief Commercial Officer
Eric Bradford

Eric Bradford

Chief Development Officer
Scott W. Rowlinson

Scott W. Rowlinson

Vice President of Research
Joseph E. Tyler

Joseph E. Tyler

Vice President of Manufacturing
Show more

Aeglea Biotherapeutics Office Locations

Aeglea Biotherapeutics has an office in Austin
Austin, US (HQ)
Barton Oaks Plaza One, 901 S MoPac Expy #250
Austin, US
805 Las Cimas Pkwy #100
Show all (2)

Aeglea Biotherapeutics Financials and Metrics

Aeglea Biotherapeutics Revenue

USD

Net income (Q3, 2020)

(18.0m)

EBIT (Q3, 2020)

(18.1m)

Market capitalization (20-Nov-2020)

413.7m

Closing stock price (20-Nov-2020)

8.6

Cash (30-Sept-2020)

54.2m

EV

364.8m
Aeglea Biotherapeutics's current market capitalization is $413.7 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.9m

General and administrative expense

8.4m10.1m12.6m15.7m

R&D expense

18.1m22.8m36.7m64.6m

Operating expense total

26.5m32.9m49.4m80.3m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

2.4m

General and administrative expense

1.8m2.4m2.1m2.4m2.4m3.0m2.9m2.9m3.3m3.3m3.8m4.3m4.5m4.7m5.7m

R&D expense

3.6m4.4m5.4m4.9m5.8m6.2m6.9m9.1m8.9m14.4m14.8m17.8m14.6m16.9m12.5m

Operating expense total

5.4m6.9m7.5m7.3m8.2m9.3m9.8m12.0m12.2m17.7m18.6m22.1m19.0m21.6m18.1m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

47.7m12.8m22.5m19.3m

Accounts Receivable

164.2m

Prepaid Expenses

1.6m2.2m2.6m

Inventories

1.7m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(21.7m)(27.2m)(44.3m)(78.3m)

Depreciation and Amortization

132.0k249.0k293.0k418.0k

Inventories

(96.1k)

Accounts Payable

(8.0k)164.0k239.0k2.6m
USDQ1, 2016

Financial Leverage

-1.3 x
Show all financial metrics

Aeglea Biotherapeutics Operating Metrics

FY, 2016

Approved Phase Products

1

Nonclinical Development

3

Phase I Trials Products

2

Phase I/II Trials Products

1
Show all operating metrics

Aeglea Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Aeglea Biotherapeutics Online and Social Media Presence

Embed Graph

Aeglea Biotherapeutics Company Culture

  • Compensation

    A+

    100/100

Learn more on Comparably

Aeglea Biotherapeutics News and Updates

Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria

AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the U.S. Food and Drug...

Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights

Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension Study

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Trial Appli…

Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones

Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Quarter of 2020, with Topline Data Expected in First Quarter of 2021

Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights

AUSTIN, Texas, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today reported financial results for the third quarter ended S…

Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights

FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency
Show more

Aeglea Biotherapeutics Blogs

Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference

Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference Content Import Tue, 11/24/2020 - 16:41 Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference 11/24/20 This release is a backfill from a News…

Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences

AUSTIN, Texas , Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in fireside

Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights

Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177   Continued Progress in Arginase 1 Deficiency Patient Identification and Engagement Efforts AUSTIN, Texas , Nov. 5, 2020 /PRNewswire/ --  Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings

AUSTIN, Texas , Oct. 5, 2020 /PRNewswire/ --  Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the presentation of a poster on

Aeglea BioTherapeutics to Participate in September Investment Conferences

AUSTIN, Texas , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in

Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020 Content Import Tue, 08/18/2020 - 16:05 Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020 08/18/20 This release is a backfill from a News Wire General…
Show more

Aeglea Biotherapeutics Frequently Asked Questions

  • When was Aeglea Biotherapeutics founded?

    Aeglea Biotherapeutics was founded in 2013.

  • Who are Aeglea Biotherapeutics key executives?

    Aeglea Biotherapeutics's key executives are Ravi M. Rao, Charles N. York and Michael C. Hanley.

  • How many employees does Aeglea Biotherapeutics have?

    Aeglea Biotherapeutics has 76 employees.

  • Who are Aeglea Biotherapeutics competitors?

    Competitors of Aeglea Biotherapeutics include METIS Precision Medicine, VelosBio and ISA Pharmaceuticals.

  • Where is Aeglea Biotherapeutics headquarters?

    Aeglea Biotherapeutics headquarters is located at Barton Oaks Plaza One, 901 S MoPac Expy #250, Austin.

  • Where are Aeglea Biotherapeutics offices?

    Aeglea Biotherapeutics has an office in Austin.

  • How many offices does Aeglea Biotherapeutics have?

    Aeglea Biotherapeutics has 2 offices.